- N Engl J Med 2022; 387:77-78
Since 1902, animals have been studied and occasionally used as sources of organs for transplantation, usually when human organs were unavailable. Clinical organ xenotransplantation invariably failed, whereas clinical organ allotransplantation rose to become a primary treatment for failure of the heart, kidneys, liver, and lungs. Still, a shortage of human...
- N Engl J Med 2022; 387:35-44
In this report, a porcine-to-human heart transplantation is described. Videos show transthoracic echocardiography in the patient who received the heart.
- N Engl J Med 2022; 386:2334-2336
Modified autologous T cells have been successfully used to treat tumors in a small proportion of patients. How can this general approach be used to treat more patients? A recent study of lymphoma, modeled in vitro, points to a potential approach.
- N Engl J Med 2022; 386:2138-2138
The editors announce a new article type, the Science behind the Study. The articles, which include illustrations and glossary terms, are meant to elucidate the scientific foundations of new clinical studies published in the Journal.
- N Engl J Med 2022; 386:992-994
Genetic landscaping and T cells are all the rage when it comes to tumor biology. Put them together and you get a comprehensive view of the T cell in the context of different types of cancer. The authors of this commentary provide a framework for a study of the RNAome...
Basic Implications of Clinical Observations: A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and VaccinationN Engl J Med 2022; 386:394-396
The authors hypothesize that anti-idiotype immune responses may contribute to rare adverse events, such as myocarditis, after SARS-CoV-2 vaccination, as well as to sequelae of Covid-19 that persist after the resolution of infection.
- N Engl J Med 2021; 385:2451-2462
Dramatic advancements in the use of synthetic and mechanical devices to replace tissues have been made, but restoring tissue and organ structure and function remains challenging. This review discusses the origins, innovations, and future of regenerative medicine and transplantation, which are closely intertwined.
- N Engl J Med 2021; 385:1807-1809
A growing body of evidence supports aberrant splicing as both a cause and a potential Achilles’ heel of cancers, especially when it comes to the effects of immune-checkpoint inhibitors.
- N Engl J Med 2021; 385:1436-1438
Although the production time (11 months) of the messenger RNA vaccines against SARS-CoV-2 infection set a record, the preclinical research undergirding them spanned decades and was challenged by lack of funding. The 2021 Lasker–DeBakey Clinical Medical Research Award goes to Drs. Drew Weissman and Katalin Karikó, pioneer researchers of modified...
- N Engl J Med 2021; 385:921-929
A young man with a germline mutation in IL2RG had a history of herpes-related encephalitis and multiple skin and mucosal lesions caused by human papillomavirus, including a recurrent refractory nasal squamous-cell carcinoma. Allogeneic hematopoietic-cell transplantation resulted in clearing of the HPV lesions, including the nasal carcinoma.
- N Engl J Med 2021; 385:658-660
Discoveries in noncoding RNA have shown it to be remarkably diverse in function and form and to have relevance in drug development. A recent study showed that some noncoding RNAs are glycosylated and sialylated and expressed on the surface of the plasma membrane. Moreover, some interact with Siglec-15, an immune...
- N Engl J Med 2021; 385:628-639
The ability to block specific cytokine pathways has revealed pathophysiological differences among autoimmune diseases (e.g., the efficacy of TNF inhibitors in arthritides and inflammatory bowel disorders and their inefficacy in giant-cell arteritis and multiple sclerosis), providing a framework for reclassification.
- N Engl J Med 2021; 385:567-569
A 20-year-old woman with refractory SLE with active lupus nephritis (WHO class IIIA), nephrotic syndrome, pericarditis, pleurisy, rash, arthritis, and a history of Libman–Sacks endocarditis refractory to conventional immunosuppression had a complete response to CD19-specific chimeric antigen receptor T cells.
- N Engl J Med 2021; 385:562-566
In this article, the authors discuss the challenges of SARS-CoV-2 infection in patients with a weakened immune system, including the potential implications regarding viral evolution and transmission.
- N Engl J Med 2021; 384:2156-2158
Recent findings based on a mouse model suggest that a peripheral immune mechanism may underlie the symptoms associated with abdominal pain in patients with irritable bowel syndrome.
- N Engl J Med 2021; 384:2039-2052
DNA mutations occur in nearly every tissue throughout the human life span and accumulate at various rates in different tissues according to intrinsic and extrinsic factors. If a mutated clone acquires features that confer a competitive advantage, clonal dominance can emerge. Such alterations can have functional consequences and cause disease.
- N Engl J Med 2021; 384:2002-2013
Fifty patients in the United States and the United Kingdom underwent HSCT with CD34+ cells transduced with a replication-defective lentivirus bearing ADA . At 24 months, all the patients were alive, and event-free survival was 96.7% among the U.S. patients and 95% among the U.K. patients. Only two patients...
- N Engl J Med 2021; 384:1468-1470
How well do serum samples from persons vaccinated with the mRNA-1273 vaccine neutralize the P.1 lineage, the B.1.1.7 lineage, the B.1.1.7 lineage plus the E484K mutation, the B.1.351 lineage, and the B.1.427/B.1.429 lineage of SARS-CoV-2? This study provides an answer.
- N Engl J Med 2021; 384:1466-1468
How well do serum samples obtained from persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages of SARS-CoV-2, first identified in Brazil, Britain, and South Africa, respectively? This study provides an answer.
- N Engl J Med 2021; 384:967-969
The immune inhibition mediated by PD-1 receptor and its ligand, PD-L1, is targeted for suppression by drugs to treat cancer. Could augmenting this inhibitory axis prevent the immune system from rejecting transplanted islet-like cells? A recent study provides a qualified answer.